Analyst consensus rating
Purple Biotech Analyst Rating: Strong Buy
PPBT is rated Strong Buy by 1 analysts with a $17.00 target. As of 2026-08-18.
Direct answer
Purple Biotech's consensus rating is Strong Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.00.
Forecast evidence checked August 18, 2026.
Get free Purple Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.56
- Average price target
- $17.00
- High price target
- $17.00
- Low price target
- $17.00
- Low target gap
- +989.7%
- Target upside
- +989.7%
- High target gap
- +989.7%
- Target range width
- 0%
- Consensus rating
- Strong Buy
- Analysts
- 1
- Evidence date
- August 18, 2026
- Valid through
- August 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Purple Biotech?
Purple Biotech has a verified Strong Buy consensus. The same dataset has an average price target of $17.00.
How far are Purple Biotech's low and high targets from the recorded price?
The low target implies +989.7%, while the high target implies +989.7%.
How many analysts are included in Purple Biotech's consensus?
The verified consensus includes 1 analysts.
How is Purple Biotech's target upside or downside calculated?
The average target of $17.00 is divided by the recorded price of $1.56, then one is subtracted to produce +989.7%. This does not guarantee a future return.
When was Purple Biotech's analyst forecast verified?
The data was verified on 2026-08-18. The dataset is valid through 2026-08-25.